+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Trintellix (vortioxetine; Lundbeck/Takeda) Drug Overview 2019

  • ID: 4846084
  • Report
  • March 2019
  • Region: Global
  • 20 pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Drug Overview
Trintellix (vortioxetine; Lundbeck/Takeda) is the latest antidepressant to be approved in the US for major depressive disorder (MDD). The drug follows a successful line of antidepressants developed by Lundbeck, which includes Cipralex (escitalopram) and Cipramil (citalopram). Trintellix was first approved in the US in September 2013 and was made commercially available in January 2014, under the brand name Brintellix. Launches throughout the EU and other countries have been staggered over 2014–16, while Trintellix remains in Phase III development in Japan. Trintellix was rebranded in the US in 2016 to distinguish itself from Brilinta (ticagrelor; AstraZeneca/The Medicines Company), after reports of medication confusion by healthcare professionals.

Trintellix was first discovered by Lundbeck and then co-developed with Takeda, which now markets the drug in the US. Trintellix is a multimodal serotonergic enhancer with activity at the serotonin receptors 5-HT3, 5-HT7, 5-HT1A, and 5-HT1B, and also at the serotonin transporter. This broad pharmacological profile results in an antidepressant activity and also the potential to improve cognitive performance among depressed patients.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
  • Drug Overview
  • Product Profiles
  • Trintellix: Depression
LIST OF FIGURES
Figure 1: The author's drug assessment summary of Trintellix for depression
Figure 2: The author's drug assessment summary of Trintellix for depression
Figure 3: Trintellix sales for depression across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Trintellix drug profile
Table 2: Approval history of Trintellix for depression in the US and five major EU markets
Table 3: Late-phase trials of Trintellix for depression
Table 4: Trintellix ongoing Phase III trials in depression
Table 5: Trintellix for depression – SWOT analysis
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll